ANALYSIS OF INTESTINAL FLORA DISORDER AND RELATED INFLUENCING FACTORS IN PATIENTS WITH COLORECTAL CANCER

Objective: To analyze intestinal flora disorder and related influencing factors in patients with colorectal cancer. Methods: 85 patients with colorectal cancer who presented in our cancer center between 2018 and September 2019 were selected to form the colorectal cancer study group, and 60 healthy individuals who visited the hospital for physical examination were selected to form the normal control group Logistic regression analysis was used to analyze the risk factors of intestinal flora abnormalities in patients with colorectal cancer. Results: The number of fecal Escherichia coli, Enterococcus faecium, and yeast in the colorectal cancer group was significantly higher than in the control group, while the number of Bifidobacterium and Lactobacillus in the colorectal cancer group was significantly lower than in the control group (P<.05). The relative content of Bacteroides and the number of butyrate-producing bacteria in the colorectal cancer group were significantly lower than in the control group (P<.05). There was no significant difference in total bacterial gene copy number, Bacteroides gene copy number, and coenzyme A (CoA) gene copy number between the two groups (P>.05). Binary logistic regression analysis showed that abnormal body mass index and medication history were risk factors for intestinal flora abnormalities in colorectal cancer patients (OR = 1.609 and 6.059, respectively; P = .003 and .036, respectively). Conclusion: The number of Escherichia coli, Enterococcus faecium and yeast in the intestinal flora of patients with colorectal cancer is significantly higher, indicating that abnormal changes in flora may be an important factor in the occurrence and development of colorectal cancer. Abnormal body mass index and medication history are risk factors for intestinal flora abnormalities in patients with colorectal cancer, and corresponding intervention measures are of great significance for the clinical treatment of colorectal cancer.